TOPAS THERAPEUTICS
Topas Therapeutics GmbH is a private Hamburg, Germany-based biotechnology company focused on developing products to address areas of major unmet need, including autoimmune diseases, allergies and anti-drug antibodies. The Topas Particle Conjugates technology platform induces antigen-specific immune tolerance by harnessing the liver’s natural immunology capabilities. The Company has several proprietary programs; lead product candidate TPM203 has recently entered clinical testing for pemphigus v... ulgaris, an orphan disease. Other programs are in anti-drug antibodies, celiac disease, Type 1 diabetes, as well as a multiple sclerosis program that is available for partnering. Topas has a research and option agreement with Eli Lilly and Company focused on antigen-specific tolerance induction and a multi-year agreement with Boehringer Ingelheim to collaborate in the field of anti-drug antibodies. Topas’ investors include: Epidarex Capital, Gimv, EMBL Ventures, Evotec and Boehringer Ingelheim Venture Fund.
TOPAS THERAPEUTICS
Social Links:
Industry:
Advanced Materials Biotechnology Chemical Chemical Engineering
Founded:
2006-01-01
Address:
Hamburg, Hamburg, Germany
Country:
Germany
Website Url:
http://www.topas-therapeutics.com
Total Employee:
51+
Status:
Active
Contact:
+49 40 302089010
Email Addresses:
[email protected]
Total Funding:
58 M EUR
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager Content Delivery Network Google Universal Analytics
Current Employees Featured
Founder
Investors List
Evotec
Evotec investment in Series B - Topas Therapeutics
Epidarex Capital
Epidarex Capital investment in Series B - Topas Therapeutics
EMBL Ventures
EMBL Ventures investment in Series B - Topas Therapeutics
Vesalius Biocapital Partners
Vesalius Biocapital Partners investment in Series B - Topas Therapeutics
BioMedPartners
BioMedPartners investment in Series B - Topas Therapeutics
Boehringer Ingelheim Venture Fund
Boehringer Ingelheim Venture Fund investment in Series B - Topas Therapeutics
Gimv
Gimv investment in Series B - Topas Therapeutics
EMBL Ventures
EMBL Ventures investment in Series B - Topas Therapeutics
Vesalius Biocapital Partners
Vesalius Biocapital Partners investment in Series B - Topas Therapeutics
Gimv
Gimv investment in Series B - Topas Therapeutics
Newest Events participated
Participated in Pre-Filled Syringes East Coast 2017
on 2017-04-26 as sponsor
Participated in Pre-Filled Syringes East Coast 2017
on 2017-04-26 as exhibitor
Key Employee Changes
| Date | New article |
|---|---|
| 2022-02-15 | Topas Therapeutics Appoints Cristina de Min, M.D. as Chief Medical Officer |
Official Site Inspections
http://www.topas-therapeutics.com
- Host name: dd24006.kasserver.com
- IP address: 85.13.146.149
- Location: Germany
- Latitude: 51.2993
- Longitude: 9.491
- Timezone: Europe/Berlin
